Joe E. Kiani, President & CEO of Masimo Corporation, was presented with the Huntington's Disease Society of America's (HDSA) Distinguished Leadership Award at the First Annual HDSA Orange County Celebration of Hope Dinner last week. The HDSA Distinguished Leadership Award is a nationally recognized award associated with the Celebration of Hope Dinners, which benefit HDSA Centers of Excellence in cities around the country. The award is presented to individuals who have had a positive impact in their communities, and for the significant contributions they have made in their chosen fields.
Mr. Kiani was recognized for his accomplishments in founding Masimo Corporation, the innovator of Masimo SET® - Signal Extraction Technology - which is used in the healthcare field as the premier noninvasive patient monitoring technology. Since its worldwide market release in 1998, Masimo SET® has emerged as the preeminent pulse oximetry (measuring a patient's arterial blood oxygen saturation) technology, particularly under the most challenging conditions of patient motion and low perfusion (low blood flow). Other recipients of the Distinguished Leadership Award included:
Ralph Cygan, M.D. - CEO of and Clinical Professor at UC Irvine Medical Center
John Hagestad - Chairman, Orangewood Children's Foundation; Executive
Committee Member, Sares Regis Group
Arthur B. Birtcher - Co-Chair, Birtcher Real Estate Group
"Huntington's Disease is a degenerative, fatal genetic disorder that can absolutely devastate families who are affected by it," said Joe E. Kiani, President and Chief Executive Officer of Masimo Corporation. "I am honored to receive the Distinguished Leadership Award, but, more importantly, I am hopeful that events such as the Celebration of Hope dinners, will serve to bring awareness and support in the fight to end Huntington's Disease."
Masimo Corporation, founded in 1989, is a privately held medical technology company that develops, licenses and markets advanced medical signal processing technologies and products for the noninvasive monitoring of vital signs. Masimo Signal Extraction Technology represents a fundamental departure from conventional pulse oximetry technologies. Over 50 independent, published studies have demonstrated that Masimo Signal Extraction Technology substantially overcomes the limitations of conventional pulse oximeters in accurately measuring arterial blood oxygen saturation levels and pulse rates in the presence of patient movement and low perfusion. To date, Masimo has licensed its Signal Extraction pulse oximetry OEM MS Boards and proprietary LNOP single patient adhesive and reusable sensors to over 35 international patient monitoring system providers which make up over 60% of the world's pulse oximeter shipments. AmeriNet, the leading group purchasing organization and HealthTrust Columbia, the largest hospital system in America are offering their member hospitals the ability to gain access to Masimo SET® technology at group purchasing discounted prices. Masimo is headquartered in Irvine, California. Additional information about Masimo and its products can be found on the company's web site www.masimo.com.
Huntington's Disease (HD), named for Dr. George Huntington who first discovered the disease in 1872, is a fatal and degenerative brain disorder for which there is, at present, no effective treatment or cure. HD, which is passed down to 50% of the children of a parent having the disorder, slowly diminishes the affected individual's ability to walk, talk and reason. The Huntington's Disease Society of America is dedicated to providing support and education to the families affected by this life-altering illness, and to ultimately finding a cure. HDSA Centers of Excellence provide clinical care, counseling, referrals and education for individuals with HD and their families. HDSA Centers of Excellence are supported through Celebration of Hope events and through the generosity of the community and HD family and friends.
